title: HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico.
abstract: OBJECTIVE
  To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals.
  
  
  METHODS
  A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary.
  
  
  CONCLUSIONS
  The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combining HPV vaccination and hrHPV-based screening to safety extend screening intervals.
authors.forename: Jorge
authors.initials: J
authors.lastname: Salmerón
authors.forename: Leticia
authors.initials: L
authors.lastname: Torres-Ibarra
authors.forename: F Xavier
authors.initials: FX
authors.lastname: Bosch
authors.forename: Jack
authors.initials: J
authors.lastname: Cuzick
authors.forename: Attila
authors.initials: A
authors.lastname: Lörincz
authors.forename: Cosette M
authors.initials: CM
authors.lastname: Wheeler
authors.forename: Philip E
authors.initials: PE
authors.lastname: Castle
authors.forename: Claudia
authors.initials: C
authors.lastname: Robles
authors.forename: Eduardo
authors.initials: E
authors.lastname: Lazcano-Ponce
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic / Q000379:methods*; D055088:Early Detection of Cancer; D005260:Female; D052140:Human papillomavirus 11 / Q000276:immunology; D052162:Human papillomavirus 16 / Q000276:immunology; D052161:Human papillomavirus 18 / Q000276:immunology; D052163:Human papillomavirus 6 / Q000276:immunology; D006801:Humans; D008800:Mexico; D008875:Middle Aged; D053918:Papillomavirus Vaccines; D011159:Population Surveillance; D011314:Preventive Health Services / Q000458:organization & administration*; D015397:Program Evaluation; D012107:Research Design; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D014611:Vaccination; D002578:Uterine Cervical Dysplasia / Q000175:diagnosis / Q000453:epidemiology / Q000821:virology
chemical_list: D053918:Papillomavirus Vaccines